ClinicalTrials.gg
RecruitingNCT06925815PregWinUpdated Apr 13, 2026

Pregnancy Cohort Study: Pregnancy as a Window to Future Health

An observational study in Healthy Pregnant Women, Obese Pregnant Women and Gestational Diabetes, sponsored by Medical University of Graz. Recruiting at 1 site in Austria. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Medical University of Graz · Observational

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 3 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
800
Ages
18 Years to 50 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Diabetes, Gestational with a site in Austria — 4 open to participants now, 5 under way, none of them phase 3. Diabetes, Gestational · Austria.

Started
2023
with 1 other
Observational
6 of 11
3 open now
Registered
8th of 11
by date
Lead sponsor
3 of 11
Medical University of Graz

Among the 11 studies in Diabetes, Gestational with a site in Austria, this one is one of 2 that started in 2023, is one of 6 observational ones, and was the 8th registered.

Diabetes, Gestational

878 studies on the registry are indexed under Diabetes, Gestational; 196 are open to participants now.

Browse Diabetes, Gestational studies →

Open to participants now

4 of the 11 studies in Diabetes, Gestational with a site in Austria are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Austria have not opened yet or have stopped. Only those recruiting at a site in Austria →

Who these studies take

Of the 132 Diabetes, Gestational studies recruiting now, 60 (45%) set no upper age limit and 70 (53%) stop at 75 or younger; 12 take children under 18; 60 take healthy volunteers.

This study: 18 Years to 50 Years · female · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Diabetes, Gestational with a site in Austria, or all of them as a file.
02

Study summary

The goal of this observational cohort study is to gain deep insights into how metabolic disorders such as obesity or diabetes during pregnancy affect the metabolic and cardiovascular health of mother and child in the short and long term.

It will investigate the following questions:

  • How do maternal metabolic disorders affect pregnancy outcomes?
  • How do maternal metabolic disorders affect fetal growth?
  • How do maternal metabolic disorders affect the newborn's metabolism and body composition?
  • How do maternal metabolic disorders during pregnancy affect breast milk composition?
  • How do maternal metabolic disorders during pregnancy affect the metabolic health of the mother after birth? Participants in this study are pregnant women who will be asked to come to the clinics for three visits during their pregnancy, as well as for the delivery of their baby, and one time 2-3 months thereafter. At each visit, researchers will perform physical examinations (such as body composition measurements) and collect biological samples (blood, urine, saliva), clinical information, and lifestyle data. At birth, researchers will collect cord blood and breast milk as well as clinical data of the delivery and the health of the baby. Researchers will measure body fat in newborn babies and at 2-3 months of age.
Read the detailed description

Pregnancy is a sensitive and determining period in life where maternal and environmental cues can influence mother and offspring health short and long term. Negative exposures in pregnancy can have long term consequences, such as higher risk for development or aggravation of obesity, metabolic and cardiovascular diseases. However, preventive measures such as life style interventions can be particularly effective (window of opportunity) and could mitigate disease trajectories.

During a healthy pregnancy, a multitude of fine-tuned physiological adaptations takes place to meet the demands of the developing fetus and prepare maternal organism for delivery and lactation. These physiological changes affect the maternal metabolism, cardiovascular system, immune system, microbiome, or endocrine system. Unfavorable or adverse maternal factors (e.g. endocrine, genetic, metabolic, lifestyle factors) may compromise these adaptations, promoting pregnancy complications such as gestational diabetes (GDM), hypertensive pregnancy diseases, fetal growth restriction, fetal overgrowth, or preterm birth. These pregnancy pathologies not only pose an immediate health risk to both mother and child, but also may negatively impact the longer-term cardiovascular, endocrine, and metabolic health of both.

Offspring exposed in utero to maternal diabetes, hypertensive diseases or maternal obesity are at higher risk of developing obesity, diabetes of cardiovascular disorders later in life. For the mother, each pregnancy loads a metabolic burden, which is aggravated by pregnancy complications, also increasing the mother's risk of developing metabolic or cardiovascular disease later in life.

Therefore, prediction and risk evaluation, early diagnosis and prognosis, safe (non-invasive) therapeutic strategies are urgently needed to provide intervention as early as possible (pre-conceptional, during pregnancy and postpartum) to avoid potential manifestations of long-term health problems. Due to the relatively short duration of pregnancy and the often increased health awareness of expectant mothers, pregnancy is an ideal phase to identify origins of disease, evaluate personalized diagnostic and predictive markers, as well as preventive strategies.

In the recent years, the concept of deep phenotyping during pregnancy has emerged as a means to tackle the current inadequate understanding on the pathobiology of pregnancy related diseases and heath trajectories.

The proposed pregnancy and birth cohort aims to meet this need providing comprehensive sets of biological samples, clinical data, physical measurements and life style information for deep phenotyping of pregnancy and early life. Special focus will be put on monitoring glucose metabolism throughout pregnancy and postpartum, since the standard care oGTT at 24 to 28 weeks merely detects an already manifest glucose intolerance without giving any information on potentially preconceptionally existing impaired glucose tolerance/pre-diabetes or predicting maternal hyperglycemia thereafter, in late pregnancy.

This study will be a monocentric, prospective cohort with the goal of recruiting 80-100 participants per year. The study will be conducted at the LKH Graz University Hospital, Department of Gynecology and Obstetrics, Outpatient Clinic. Women with child wish will be recruited at the Center for Assisted Reproductive Technologies (Center for Gynecologic Endocrinology and Reproductive Medicine, Kinderwunsch-Zentrum) or pregnant women attending their routine first trimester screening visits will be enrolled and followed throughout their pregnancy until 8-12 weeks postpartum. There will be up to 6 visits: (T0 preconceptional enrollment), T1 (10-14 weeks of gestation, first trimester screening/enrollment), T2 (24-28 weeks of gestation, time of routine care oGTT); T3 (34-37 weeks of gestation, late pregnancy control visit in preparation for delivery), T4 (delivery), T5 (8-12 weeks postpartum; follow-up after pregnancy complications). The study is designed to closely monitor glucose metabolism and requires participants to be fasting for blood sampling. Women will be offered an oGTT at each visit (at T2 standard of care), but may opt out.

The study will collect clinical markers and measurements of metabolic and hemodynamic parameters, as well as a comprehensive collection of biospecimens and metadata on lifestyle factors (nutrition, physical activity). Advanced methods such as maternal and infant air displacement plethysmography (BODPOD /PEAPOD) will provide accurate body composition measurements. Endothelial/vascular function is assessed by hemodynamic parameters, including pulse wave velocity measured with a Vicorder®.

03

Conditions studied

  • Healthy Pregnant Women
  • Obese Pregnant Women
  • Gestational Diabetes

Keywords

  • pregnancy
  • deep phenotyping
  • maternal metabolism
  • body composition
  • longitudinal pregnancy cohort study
  • fetal growth
  • obesity in pregnancy
  • neonatal adiposity
  • gestational weight gain
  • gestational diabetes
  • cardiovascular health
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Eligible for participation are women with child wish and women with an on-going pregnancy who are planning to give birth at the university hospital in Graz, Austria. Women will be recruited as soon as possible in their pregnancy, but not after the 14th week of gestation. They will be recruited through the outpatient clinics and, in case of women with child wish, at the center for assisted reproductive technologies at the Department of Obstetrics and Gynecology, at Medical University Graz.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • ongoing pregnancy prior to 14th gestational week, women with child wish; above 18 years of age, giving

Exclusion criteria

Exclusion Criteria:

  • gestational age > 14th week of gestation; below 18 years of age; fetal genetic anomalies /malformation
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
800 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Maternal adiposity

    Measured as fat mass and fat-free mass by air displacement plethysmography (via BODPOD) at 10-14 weeks, 20-24 weeks and 34-37 weeks of gestation and 8-12 weeks post partum.

    Time frame: From enrolment to 8-12 weeks post partum

  2. Maternal fasting blood glucose

    Fasting blood glucose as measured in mg/mL from NaF blood tubes at 10-14 weeks, 24-24 weeks, 34-37 weeks of gestation and 8-12 postpartum.

    Time frame: from enrollment to 8-12 weeks postpartum

  3. Maternal blood pressure

    Blood pressure will be measured at 10-14 weeks, 24-28 weeks and 34-37 weeks of gestation and 8-12 weeks post partum.

    Time frame: From enrolment to 8-12 weeks postpartum

  4. Maternal lipid profiles - triglycerides

    Analysis of serum lipid profiles: triglycerides at 3 time points during pregnancy (10-14 weeks (wks); 24-28wks; 34-37wks), and 8-12 wks postpartum.

    Time frame: From enrolment to 8-12 weeks post partum

  5. Maternal lipid profiles: phospholipids

    Analysis of serum lipid profiles: phospholipids at 3 time points during pregnancy (10-14wks; 24-28wks; 34-37wks), and 8-12wks postpartum.

    Time frame: From enrolment to 8-12 weeks post partum

  6. Maternal lipid profiles: free fatty acids

    Analysis of serum lipid profiles: free fatty acids at 3 time points during pregnancy (10-14wks; 24-28wks; 34-37wks), and 8-12wks postpartum.

    Time frame: From enrolment to 8-12 weeks post partum

  7. Maternal lipid profiles: total cholesterol

    Analysis of serum lipid profiles: total cholesterol at 3 time points during pregnancy (10-14wks; 24-28wks; 34-37wks), and 8-12wks postpartum.

    Time frame: From enrolment to 8-12 weeks post partum

  8. Maternal lipid profiles: HDL cholesterol

    Analysis of serum lipid profiles: HDL cholesterol at 3 time points during pregnancy (10-14wks; 24-28wks; 34-37wks), and 8-12wks postpartum.

    Time frame: From enrolment to 8-12 weeks post partum

  9. Maternal lipid profiles: LDL cholesterol

    Analysis of serum lipid profiles: LDL cholesterol at 3 time points during pregnancy (10-14wks; 24-28wks; 34-37wks), and 8-12wks postpartum.

    Time frame: From enrolment to 8-12 weeks post partum

  10. Maternal endothelial function

    measured as pulse wave velocity using a Vicorder®.

    Time frame: From enrolment to 8-12 weeks post partum

  11. Maternal cytokine profile

    Serum cytokines will be analysed by multiplexing at all visits during pregnancy and postpartum.

    Time frame: From enrolment to 8-12 weeks postpartum

  12. Gestational diabetes

    assessed through 75g 2h oral glucose tolerance test performed at 24-28 weeks of gestation.

    Time frame: From enrolment to child birth; 6 months

  13. Hypertensive disorders of pregnancy

    gestational hypertension and preeclampsia, assessed through medical chart review.

    Time frame: From enrolment to child birth; 6 months

  14. Neonatal body composition at birth

    Measured as fat mass and fat-free mass by air displacement plethysmography (via PEAPOD)

    Time frame: between delivery and 48h postpartum

  15. Neonatal C-peptide in cord blood

    Concentrations of C-peptide in cord blood

    Time frame: at birth

  16. Neonatal cytokine profile

    Neonatal inflammatory cytokines will be measured in cord blood serum collected at birth using multiplexing cytokine assays.

    Time frame: at birth

  17. Neonatal epigenetic profile

    Epigenomic profile of the umbilical cord blood measured by DNA methylation

    Time frame: at birth

Secondary outcomes

  1. Human milk oligosaccharide (HMO) profile in maternal blood

    HMOs will be analysed in maternal serum by high pressure liquid chromatography (HPLC) with fluorescence detection

    Time frame: From enrolment to 8-12 weeks postpartum

  2. Human milk oligosaccharide (HMO) profile in maternal urine

    HMOs will be analysed in maternal serum by high pressure liquid chromatography (HPLC) with fluorescence detection

    Time frame: From enrolment to 8-12 weeks post partum

  3. Human milk oligosaccharide (HMO) profile in cord blood

    HMOs will be analysed in umbilical cord blood serum by high pressure liquid chromatography (HPLC) with fluorescence detection

    Time frame: at birth

  4. Human milk oligosaccharide (HMO) profile in breast milk

    HMOs will be analysed in breast milk by high pressure liquid chromatography (HPLC) with fluorescence detection

    Time frame: from child birth to 8-12 weeks postpartum

  5. Adverse pregnancy outcome

    Composite measure including gestational hypertension, preeclampsia, gestational diabetes, preterm delivery, low birth weight, assessed through medical chart review

    Time frame: From enrolment to child birth; 6 months

Other outcomes

  1. Maternal vaginal microbiome

    From the extracted DNA, 16S rRNA genes will be amplified using specific primers for bacterial and archaeal communities. The amplicons obtained will be prepared for Illumina MiSeq Sequencing.

    Time frame: From enrolment to 8-12 weeks postpartum

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All IPD underlying results in a publication will be shared.

Supporting information: Study protocol, Informed consent form

Time frame: Data will be made available starting 1 year after publication with no end date.

Access criteria: Data access will be provided to external researchers who submit a methodologically sound proposal for secondary data analysis that is approved by the study investigators and should be submitted to the study PI.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2023 (actual). Primary completion is estimated for Jun 2033, 119 months after the start.

Of 142 non-industry observational studies under Diabetes, Gestational, half reached primary completion within 42 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 70. This study's planned 119 months is above that.

Counting every sponsor, half of 144 studies reached it within 43 months; a quarter within 19 and three quarters within 73.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 13, 2025
StartActual
Jul 27, 2023
Primary completionEst.
Jun 2033
CompletionEst.
Jun 2034
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06925815
Responsible party
Sponsor
First posted
Apr 13, 2025
Start date
Jul 27, 2023
Primary completion
Jun 2033 (estimated)
Completion
Jun 2034 (estimated)
Last update
Apr 13, 2026

Study contacts

Evelyn Jantscher-Krenn, PhD
Contact
evelyn.jantscher-krenn@medunigraz.at
+43 316 385 80076
Christina Stern, Dr. med.
Contact
christina.stern@medunigraz.at
+43 316 385 86306
Evelyn Jantscher-Krenn, PhD
principal investigator · Medical University of Graz
Herbert Fluhr, Univ.-Prof. Dr. med.
study director · Medical University of Graz
Ursula Hiden, Assoc. Prof.
principal investigator · Medical University of Graz
Christina Stern, Dr. med.
principal investigator · Medical University of Graz
Federica Piani, MD, PhD
principal investigator · Medical University of Graz

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion